癌基因
生物
基因产物
免疫组织化学
病理
单克隆抗体
癌症研究
表位
癌症
糖蛋白
乳腺癌
基因
基因表达
抗体
医学
免疫学
细胞周期
分子生物学
遗传学
作者
Pier Giorgio Natali,Maria Rita Nicotra,A Bigotti,I Venturo,Dennis J. Slamon,B M Fendly,Axel Ullrich
标识
DOI:10.1002/ijc.2910450314
摘要
Abstract The human homolog of the rat neu oncogene, HER2 (also termed c‐ erb B2) has been demonstrated in amplified form in human breast tumors with poor prognosis. Although amplification of the gene correlates with expression of a 185‐kDa transmembrane glycoprotein, no extensive information is available regarding the extent of tissue and tumor specificity of this gene product. We have addressed this issue by immunohistochemically evaluating the expression of p185 HER2 in normal tissue and various tumors using monoclonal antibodies (MAbs) to distinct epitopes of its extracellular domain. No detectable levels of p185 HER2 were found in fetal tissues analyzed, with the exception of renal tubules in 2 out of 3 specimens tested and in intestinal epithelium. In adult tissues, detectable levels of this glycoprotein were found in a restricted number of cell types, the expression being heterogeneous among individuals and cell histotypes. Among the neoplasms assayed p185 HER2 was expressed in 46% of primary breast cancers, in 28% of ovarian tumors and in 30% of colon rectum malignancies. No male breast adenocarcinomas were p185‐positive. A large number of other tumors tested revealed only a low incidence of expression of the p185. In metastatic breast tumors p185 HER2 was demonstrated homogeneously among multiple autologous lesions and almost invariably (80%) the expression of p185 in the primary lesion correlated with that of the deriving metastases. Our findings indicate that the expression of the p185 HER2 represents a tumor marker of clinical relevance in breast cancer. Whether this holds true for other malignancies remains to be explored.
科研通智能强力驱动
Strongly Powered by AbleSci AI